Iconoclast,

You've been around this forum long enough to know that there is no way to know that answer. I can't even call it ignorance since you should know better. Once again, this lower than expected observed event rate may be due to 1) the entire trial population having a lower residual MACE rate than originally projected (i.e. the placebo event rate); 2) apabetalone lowering the MACE incidence to a greater degree than expected; or 3) a combination of both. 

BearDownAZ